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Background: Community-associated infections caused by extended-spectrum beta-lactamase (ESBL) producing
bacteria are a growing concern.
Methods: Retrospective cohort study of clinical infections due to ESBL-producing bacteria requiring admission from
2006-2011 at a tertiary care academic medical center in Providence, RI.
Results: A total of 321 infections due to ESBL-producing bacteria occurred during the study period. Fifty-eight cases
(18%) were community-acquired, 170 (53%) were healthcare–associated, and 93 (29%) were hospital-acquired. The
incidence of ESBL infections per 10,000 discharges increased during the study period for both healthcare-associated
infections, 1.9 per year (95% CI 1-2.8), and for community-acquired infections, 0.85 per year (95% CI 0.3-1.4) but the
rate remained unchanged for hospital-acquired infections. For ESBL-producing E. coli isolates, resistance to both
ciprofloxacin and trimethoprim-sulfamethoxazole was 95% and 65%, respectively but 94% of isolates were
susceptible to nitrofurantoin.
Conclusions: Community-acquired and healthcare-associated infections due to ESBL-producing bacteria are
increasing in our community, particularly urinary tract infections due to ESBL-producing E. coli. Most isolates are
resistant to oral antibiotics commonly used to treat urinary tract infections. Thus, our findings have important
implications for outpatient management of such infections.
Keywords: Extended-spectrum beta-lactamase, Urinary tract infection, Antimicrobial resistance, Community-
acquired infections, CiprofloxacinBackground
ESBL-producing bacteria cause infections in hospitalized
patients [1-3], patients housed in long-term care facil-
ities [4,5], and they are gaining a foothold in commu-
nity settings [6,7]. Human fecal carriage with these
microorganisms is increasing, as well as their ubiquity
in non-human species [8]. The increasing prevalence
of infections due to ESBL-producing bacteria creates a
challenge regarding appropriate antimicrobial therapy,
especially in the community setting where oral antibi-
otics are used.* Correspondence: lmermel@lifespan.org
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article, unless otherwise stated.Most ESBLs are found in Escherichia coli and Klebsiella
pneumoniae, frequently harboring resistance to other clas-
ses of antibiotics [9,10]. The majority of infections caused
by these pathogens are urinary tract infections with oc-
casional secondary bloodstream infections. In general,
the preferred antibiotic class for management of infec-
tions due to ESBL-producing bacteria are carbapenems
[11]. The purpose of this study was to better understand
the changing epidemiology of ESBL-producing bacteria.Methods
Study population
This study was conducted at Rhode Island Hospital, a ter-
tiary care hospital licensed for 719 beds in Providence, RI.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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This was an IRB-approved, retrospective cohort study of
all adult patients hospitalized between January 2006
through December 2011 who had a positive clinical
culture for an ESBL-producing microorganism.Microbiology
Clinical cultures were identified and tested for antimicro-
bial susceptibility utilizing the Vitek 2 System (bioMérieux,
Inc. Durham, NC). The detection of ESBL in E. coli and
K. pneumoniae was done as previously described [12].
The phenotype confirmatory test for ESBL production
was performed with use of ceftazidime (30 μg) and cefo-
taxime (30 μg), with and without clavulanic acid, against
the isolates. The discs were placed on pre-inoculated
Mueller-Hinton agar and incubated at 37°C. A difference
of ≥5 mm between the zone diameters of either of the
cephalosporin disks and their respective cephalosporin/
clavulanate disk was considered phenotypic confirmation
of ESBL production.Demographic and clinical data
Cases were identified using infection control software
(Theradoc, Hospira Inc. Lake Forest, IL). Cases were
included if all three of the following were documented:
an ESBL-producing microorganism was grown from a
patient’s clinical specimen; the treating physician noted
that the patient had an infection in the medical record;
and the physician treated the patient with antibiotics. All
charts were reviewed by one of the study authors (SK) to
determine the infection acquisition type (i.e., community-
acquired, healthcare-associated or hospital-acquired) using
the Centers for Disease Control and Prevention definitions
[13]. The antibiogram was obtained from the electronic
medical record.Definitions
The site of infection was defined according to CDC defini-
tions [14]. If a culture was obtained more than 48 hours
after hospital admission, it was classified as hospital-
acquired. If a culture was obtained within 48 hours after
admission, it was classified as a healthcare-associated in-
fection if a) within the prior 90 days the patient resided in
a long-term care facility or, had an prior admission to an
acute-care facility in our hospital system, or an outside
hospital as mentioned in the admission note; b) or had
undergone hemodialysis or received an intravenous medi-
cations or c) if they underwent an invasive procedure
within the last 30 days prior to admission. Otherwise, a
patient was considered to have a community-acquired
infection.Statistical analysis
Age comparisons between the three groups were analyzed
using a two-tailed t test. Sex differences among the three
groups were analyzed using chi-square testing. Linear re-
gression was performed to determine whether changes in
the incidence of infection were statistically significant
(SPSS, Chicago, IL). This analysis was repeated including
only the first occurrence of an infection in a given patient.
Differences in antibiotic resistance between acquisition
groups were analyzed using either a chi-square test or a
Fischer exact test when appropriate. Use of a two-tailed
test of significance with a P-value <0.05 was employed to
determine statistical significance.
Results
During the study period, there were 321 incident infec-
tions due to ESBL-producing bacteria. Twenty-six patients
experienced more than one infection. One patient had
two different ESBL-producing bacteria in the same clinical
sample at one time. The number of infections due to these
pathogens increased consistently from 23 infections in
2006 to 81 in 2011 (Figure 1). Overall, 58 cases (18%) were
community-acquired, 170 (53%) healthcare–associated,
and 93 (29%) hospital-acquired. The incidence of infection
due to ESBL-producing bacteria per 10,000 discharges
increased significantly during the study period for health-
care associated infections, 1.9 per year (95% CI 1-2.8;
p = .003) and for community-acquired infections, 0.85
per year (95% CI 0.3-1.4; p = .01). There was no signifi-
cant change in the hospital-acquired infection group.
When this analysis was repeated after removing 26 re-
current episodes of infections, none of the significant
changes over time became non-significant (data not
shown).
The mean age among the three groups was 69, 70 and
65 years in the community, healthcare and hospital-
acquired infection groups, respectively. The difference in
age between the healthcare-associated and the hospital-
acquired infection groups was significant (p = 0.04). There
were fewer males (26%) in the community-acquired group
compared with healthcare-associated (42%) and hospital-
acquired groups (41%; p = 0.1).
Urinary tract infection predominated (80%), followed by
bloodstream infection (10%), skin and soft-tissue infection
(5%), pneumonia (3%) and intra-abdominal infection (2%).
There was a marked shift in the predominant organism in
all three acquisition types from K. pneumoniae to E. coli
(Figure 2). For the entire study period, E. coli accounted
for 78%, 66% and 65% of the community, healthcare-
associated, and hospital-acquired groups, respectively.
Resistance to trimethoprim-sulfamethoxazole (TMP-
SMZ) and ciprofloxacin was commonly observed among
E. coli isolates (Table 1); however, 94% of E. coli isolates
were susceptible to nitrofurantoin with no difference
Figure 1 Origin of infection due to ESBL-producing bacteria. Incidence of infections due to ESBL-producing bacteria by classification of origin
over the study period.
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all K. pneumoniae isolates were resistant to nitrofurantoin.Discussion
The number of infections due to ESBL-producing bac-
teria are increasing, especially community or non-hospital
healthcare-associated infections as demonstrated by others
[15,16]. Although the focus of infection control measures
has been on transmission of such pathogens within hospi-
tals, many of the infections due to ESBL-producing bacteriaFigure 2 ESBL-producing bacteria. ESBL-producing bacteria identified duappear to arise outside of the acute-care setting where
there is limited infection control resources [17].
We found high levels of resistance to TMP-SMZ and
ciprofloxacin in all acquisition types. E. coli resistance to
TMP-SMZ was similar to other studies [18]; however,
ciprofloxacin resistance among E. coli in our study (95%)
is higher than found in other reports [10,15,16,19-21].
The level of ciprofloxacin resistance we documented in
our community-acquired ESBL-producing E. coli (92%)
is also higher than the level of resistance among all
E. coli isolates tested at our hospital in 2011 (31%) [22].ring the study period.
Table 1 Antimicrobial resistance of ESBL-producing E. coli
Antimicrobial Community acquired Healthcare associated Hospital acquired Total P value
Bacteria n(%) Resistant Bacteria n(%) Resistant Bacteria n(%) Resistant Bacteria n(%) Resistant
TMP-SMZ* 51 32 (69) 111 75 (68) 57 45 (79) 219 152 (69) 0.2
Ciprofloxacin 52 48 (92) 111 109 (98) 57 53 (92) 220 210 (95) 0.1
Nitrofurantoin 50 3 (6) 85 7 (8) 43 1 (2) 178 11 (6) 0.5
Legend: *Trimethoprim-sulfamethoxazole.
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harbor additional resistance genes, it remains unclear why
our isolates had such high levels of ciprofloxacin resist-
ance. One possibility is that the CTX-M was the predom-
inant gene regulating beta-lactamase production in most
of our isolates. While we did not investigate the molecular
mechanisms of resistance in our study, we wonder
whether our isolates which showed the persistently
increasing predominance of E. coli may indeed be the
advance of CTX-M in our region, as has been found in
rectal colonizers in other patients admitted to our hospital
(L.A. Mermel, unpublished data, February 2013). Of note,
a US multi-centered study documented 99% ciprofloxacin
resistance among CTX-M-containing E. coli [23] and a
recent US multi-centered study of community-acquired
E. coli ESBL infections found the majority contained
CTX-M genes [15]. This finding raises concern for
treatment failure in the community setting given the
levels of resistance to antimicrobial agents commonly
used for cystitis, namely TMP-SMZ and ciprofloxacin.
We found a low level of nitrofurantoin resistance in our
E. coli isolates. As such, patients in our study with
community-acquired infections may have been outpatient
treatment failures owing to initial empiric therapy with
either ciprofloxacin or TMP-SMZ, prompting hospital
admission. While we did not have susceptibility data to
fosfomycin, a recent study found no resistance among
community-acquired ESBL-producing E. coli [16]. Thus,
it seems prudent to consider the use of nitrofurantoin
or fosfomycin as empiric therapy for acute uncomplicated
cystitis in those at risk for, or with a history of infection or
colonization with an ESBL-producing E. coli.
What accounts for the increasing numbers of ESBL-
producing E. coli and the increase in community-acquired
infections? Traditionally, K. pneumoniae made up the
majority of infections due to ESBL-producing pathogens
and the majority of those occurred in hospital settings.
However, 88% of our community-acquired isolates of
ESBL-producing bacteria in 2011 were E. coli, a marked
shift from four years earlier when it was 55%. The presence
of ESBL-producing E. coli as commensal flora in healthy
livestock has been documented throughout Europe and
Asia with as many as 40% of poultry populations colonized
with these bacteria and their presence has been identified
in retail meats [8,24,25]. Additionally, several studies havefound ESBL-producing E. coli in the fecal flora of healthy
companion animals, namely cats and dogs, and recently
such isolates have been detected in US animals, where
the predominant strain was CTX-M [8,26]. Beyond do-
mesticated animals, ESBL-producing E. coli have been
found in wildlife in several continents and many such
isolates have been shown to be genotypically-related to
human isolates [27].
Regarding limitations in our study, it is possible that
patients were misclassified as community-acquired given
the lack of available documentation in the medical rec-
ord. Given the lack of admission screening, it is possible
that some cases deemed hospital-acquired infections
were community-acquired. Our community-acquired
cohort is likely a biased subset as they required hospital
admission, thus indicating that they likely were more
ill than those whom developed such infections and
remained in the community. Additionally, our anti-
biotic resistance patterns for the community-acquired
and healthcare-associated organisms likely present a
biased sample as only those patients ill enough to require
admission are represented. Use of the Vitek 2 system alone
for identification of ESBL-producing Enterobacteriacae is
insufficient [28]. As such, our laboratory used confirma-
tory testing as noted in the Methods section. Lastly,
our laboratory uses CLSI breakpoints for susceptibilty
testing. The CLSI has updated recommendations for
interpretation of antibiotic susceptibility testing results
in the 2010 and 2011 CLSI guidelines, in part adopting
European Committee for Antimicrobial Susceptibility
Testing (EUCAST) strategies. The CLSI now recommends
higher zone diameter susceptibility breakpoints for 3rd
generation cephalosporins and carbapenems; fluoroquino-
lone breakpoints were unchanged. Thus, our data must be
interpreted in context, based on previously used CLSI
breakpoints rather than revised CLSI breakpoints or those
recommended by EUCAST [29].
Conclusion
In summary, our study noted the emergence of community-
acquired infections due to ESBL-producing bacteria, a
marked increase in healthcare-associated infections, as
well E. coli becoming the predominant pathogen in all
three acquisition groups. We found high levels of TMP-
SMZ and ciprofloxacin resistance. This has implications
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these frequently utilized antibiotics in the outpatient set-
ting are ineffective for such pathogens. Another important
finding is the susceptibility of ESBL-producing E. coli
to nitrofurantoin. Further elucidation of underlying
genetic makeup of ESBL-producing pathogens will as-
sist in better understanding the epidemiology of these
emerging infections.
Abbreviations
ESBL: Extended-spectrum beta-lactamase; TMP-SMZ: Trimethoprim-
sulfamethoxazole.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SZK and LAM are both fully responsible for the entirety of the study from
conception through critical revisions of the manuscript. Both SZK and LAM
had full access to all the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis. Both authors
approved the final manuscript.
Acknowledgements
Stephen Parenteau, MS, Department of Infection Control and Epidemiology,
Rhode Island Hospital, Providence, RI, provided assistance with data
extraction from the infection control database. Kimberle Chapin, MD,
Director of Microbiology, Rhode Island Hospital, Providence, RI, provided the
on line data in reference [22].
Author details
1Department of Medicine, Warren Alpert Medical School of Brown University,
Providence, RI, USA. 2Department of Epidemiology and Infection Control,
Rhode Island Hospital, 593 Eddy Street, Providence RI 02903, USA. 3Division of
Infectious Diseases, Rhode Island Hospital, 593 Eddy Street, Providence, RI
02903, USA.
Received: 27 December 2013 Accepted: 23 January 2014
Published: 25 March 2014
References
1. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak of
Klebsiella infection resistant to late-generation cephalosporins. Ann Intern
Med 1993, 119(5):353–358.
2. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H,
Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener
MM, McCormack JG, Yu VL: International prospective study of Klebsiella
pneumoniae bacteremia: implications of extended-spectrum beta-
lactamase production in nosocomial Infections. Ann Intern Med 2004,
140(1):26–32.
3. Alcantar-Curiel D, Tinoco JC, Gavosso C, Carlos A, Daza C, Perez-Prado MC,
Salcido L, Santos JI, Alpuche-Aranda CM: Nosocomial bacteremia and
urinary tract infections caused by extended-spectrum beta -lactamase-
producing Klebsiella pneumoniae with plasmids carrying both SHV-5
and TLA-1 genes. Clin Infect Dis 2004, 38(8):1067–1074.
4. Trick WE, Weinstein RA, DeMarais PL, Kuehnert MJ, Tomaska W, Nathan C,
Rice TW, McAllister SK, Carson LA, Jarvis WR: Colonization of skilled-care
facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc
2001, 49(3):270–276.
5. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein
RA: Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing
homes. JAMA 1999, 281(6):517–523.
6. Pitout JD, Nordmann P, Laupland KB, Poirel L: Emergence of
Enterobacteriaceae producing extended-spectrum beta-lactamases
(ESBLs) in the community. J Antimicrob Chemother 2005, 56(1):52–59.
7. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, Azap
OK, Arpin C, Pascual A, Livermore DM, Garau J, Carmeli Y: A multinational
survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis
2009, 49(5):682–690.
8. Smet A, Martel A, Persoons D, Dewulf J, Heyndrickx M, Herman L,
Haesebrouck F, Butaye P: Broad-spectrum beta-lactamases among
Enterobacteriaceae of animal origin: molecular aspects, mobility and
impact on public health. FEMS Microbiol Rev 2010, 34(3):295–316.
9. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M,
Chmelnitsky I, Leavitt A, Carmeli Y: Influx of extended-spectrum beta-
lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis
2006, 42(7):925–934.
10. Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, deCueto M, Rios MJ,
Hernandez JR, Pascual A: Bacteremia due to extended-spectrum
beta -lactamase-producing Escherichia coli in the CTX-M era: a new
clinical challenge. Clin Infect Dis 2006, 43(11):1407–1414.
11. Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing
Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis
2008, 8(3):159–166.
12. Institute, C.a.L.S: Performance Standards for Antimicrobial Susceptibility Testing.
Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
13. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for
nosocomial infections, 1988. Am J Infect Control 1988, 16(3):128–140.
14. Prevention, C.f.D.C.a: CDC/NHSN Surveillance Definition of Healthcare-
Associated Infection and Criteria for Specific Types of Infections in the Acute
Care Setting; 2013. Available from: http://www.cdc.gov/nhsn/pdfs/
pscmanual/17pscnosinfdef_current.pdf.
15. Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM, Lewis JS
2nd, Howard WJ, Johnson LE, Polsky B, Jorgensen JH, Richter SS, Shutt KA,
Paterson DL: Community-associated extended-spectrum beta-lactamase-
producing Escherichia coli infection in the United States. Clin Infect Dis
2013, 56(5):641–648.
16. Meier S, Weber R, Zbinden R, Ruef C, Hasse B: Extended-spectrum beta-
lactamase-producing Gram-negative pathogens in community-acquired
urinary tract infections: an increasing challenge for antimicrobial
therapy. Infection 2011, 39(4):333–340.
17. Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF: Rate of transmission
of extended-spectrum Beta-lactamase-producing enterobacteriaceae without
contact isolation. Clin Infect Dis 2012, 55(11):1505–1511.
18. Lewis JS 2nd, Herrera M, Wickes B, Patterson JE, Jorgensen JH: First report
of the emergence of CTX-M-type extended-spectrum beta-lactamases
(ESBLs) as the predominant ESBL isolated in a U.S. health care system.
Antimicrob Agents Chemother 2007, 51(11):4015–4021.
19. Pitout JD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey MR,
Laupland KB: Molecular epidemiology of CTX-M-producing Escherichia
coli in the Calgary Health Region: emergence of CTX-M-15-producing
isolates. Antimicrob Agents Chemother 2007, 51(4):1281–1286.
20. Bonkat G, Müller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, Wyler S,
Gasser TC, Bachmann A, Widmer AF: Increasing prevalence of
ciprofloxacin resistance in extended-spectrum-b-lactamase-producing
Escherichia coli urinary isolates. World J Urol 2013, 31(6):1427–1432.
21. Tinelli M, Cataldo MA, Mantengoli E, Cadeddu C, Cunietti E, Luzzaro F,
Rossolini GM, Tacconelli E: Epidemiology and genetic characteristics of
extended-spectrum beta-lactamase-producing Gram-negative bacteria
causing urinary tract infections in long-term care facilities. J Antimicrob
Chemother 2012, 67(12):2982–2987.
22. 2011 Rhode Island Hospital Clinical Microbiology Laboratory Antimicrobial
Statistics Data. [cited 2012 28 November 2012]; Available from: http://intra.
lifespan.org/rih/microbiology/documents/2011RIHInpt.pdf.
23. Johnson JR, Urban C, Weissman SJ, Jorgensen JH, Lewis JS 2nd, Hansen G,
Edelstein PH, Robicsek A, Cleary T, Adachi J, Paterson D, Quinn J, Hanson
ND, Johnston BD, Clabots C, Kuskowski MA, AMERECUS Investigators:
Molecular epidemiological analysis of Escherichia coli sequence type
ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-beta-
lactamase-producing E. coli from the United States, 2000 to 2009.
Antimicrob Agents Chemother 2012, 56(5):2364–2370.
24. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J, Voets GM, van den
Munckhof MP, van Essen-Zandbergen A, Platteel T, Fluit AC, van de Sande-
Bruinsma N, Scharinga J, Bonten MJ, Mevius DJ, National ESBL surveillance
group: Dutch patients, retail chicken meat and poultry share the same
ESBL genes, plasmids and strains. Clin Microbiol Infect 2011, 17(6):873–880.
25. Kluytmans JA, Overdevest IT, Willemsen I, Kluytmans-van den Bergh MF, van
der Zwaluw K, Heck M, Rijnsburger M, Vandenbroucke-Grauls CM, Savelkoul PH,
Kassakian and Mermel Antimicrobial Resistance and Infection Control 2014, 3:9 Page 6 of 6
http://www.aricjournal.com/content/3/1/9Johnston BD, Gordon D, Johnson JR: Extended-spectrum beta-lactamase-
producing Escherichia coli from retail chicken meat and humans:
comparison of strains, plasmids, resistance genes, and virulence factors. Clin
Infect Dis 2013, 56(4):478–487.
26. O’Keefe A, Hutton TA, Schifferli DM, Rankin SC: First detection of CTX-M
and SHV extended-spectrum beta-lactamases in Escherichia coli urinary
tract isolates from dogs and cats in the United States. Antimicrob Agents
Chemother 2010, 54(8):3489–3492.
27. Guenther S, Ewers C, Wieler LH: Extended-spectrum beta-lactamases
producing E. coli in wildlife, yet another form of environmental
pollution? Front Microbiol 2011, 2:1–13.
28. Espinar MJ, Rocha R, Ribeiro M, Goncalves Rodrigues A, Pina-Vaz C:
Extended-spectrum beta-lactamases of Escherichia coli and Klebsiella
pneumoniae screened by the VITEK 2 system. J Med Microbiol 2011,
60(Pt 6):756–760.
29. Hombach M, Mouttet B, Bloemberg GV: Consequences of revised CLSI and
EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and
AmpC beta-lactamase-producing clinical Enterobacteriaceae isolates.
J Antimicrob Chemother 2013, 68(9):2092–2098.
doi:10.1186/2047-2994-3-9
Cite this article as: Kassakian and Mermel: Changing epidemiology of
infections due to extended spectrum beta-lactamase producing
bacteria. Antimicrobial Resistance and Infection Control 2014 3:9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
